• 1
    Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010; 30: 101426.
  • 2
    Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Peluso R, Coppola A, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherosclerosis. Semin Thromb Hemost 2012; 38: 497505.
  • 3
    Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 295763.
  • 4
    Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 273745.
  • 5
    Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 58592.
  • 6
    Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 32732.
  • 7
    Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 9728.
  • 8
    Zulet MA, Puchau B, Navarro C, Marti A, Martinez JA. Inflammatory biomarkers: the link between obesity and associated pathologies. Nutr Hosp 2007; 22: 51127.
  • 9
    Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 8190.
  • 10
    Hermsdorff HH, Zulet MA, Abete I, Martinez JA. Discriminated benefits of a Mediterranean dietary pattern within a hypocaloric diet program on plasma RBP4 concentrations and other inflammatory markers in obese subjects. Endocrine 2009; 36: 44551.
  • 11
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 266573.
  • 12
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 5578.
  • 13
    Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G, on behalf of the CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Artherioscler Thromb Vasc Biol 2011; 31: 70512.
  • 14
    World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000; 894: i–xii, 1253.
  • 15
    Di Minno MN, Tufano A, Guida A, Di Capua M, De Gregorio AM, Cerbone AM, et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res 2011; 127: 1937.
  • 16
    Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62: 9659.
  • 17
    Coates LC, Cook R, Lee K, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010; 62: 9706.
  • 18
    Iervolino S, Di Minno MN, Peluso R, Lofrano M, Russolillo A, Di Minno G, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol 2012; 39: 56873.
  • 19
    Dixon WG, Symmons DP. What effects might anti-TNF-α treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF-α in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 11326.
  • 20
    Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 15037.
  • 21
    Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 34958.
  • 22
    Rocha VZ, Libby P. The multiple facets of the fat tissue. Thyroid 2008; 18: 17583.
  • 23
    Van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65: 15517.
  • 24
    Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis [letter]. Intern Emerg Med 2012; 7 Suppl 2: 978.
  • 25
    Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis on TNF-α blockers. J Rheumatol 2012; 39: 10426.
  • 26
    Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. Assessment of SpondyloArthritis international Society. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 9058.
  • 27
    Olivieri I, Mantovani LG, D'Angelo S, Padula A, de Portu S. Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep 2009; 11: 2639.
  • 28
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 227585.